Survodutide for fatty liver: what SYNCHRONIZE-MASLD found

What MASLD is and why liver fat accumulation matters

The liver is not supposed to store fat. When it does, it signals something is off in the broader metabolic picture: too much insulin resistance, too much visceral fat, too little clearance of fatty acids from the bloodstream. Fatty liver is not just a liver problem. It reflects the same metabolic dysfunction that drives obesity, type 2 diabetes, and cardiovascular disease.

MASLD, metabolic dysfunction-associated steatotic liver disease, is the umbrella term for that condition. It replaced NAFLD in 2023. Roughly 40% of the global population has some degree of it. Most never progress beyond fatty infiltration. A subset develops MASH, metabolic-associated steatohepatitis, which adds inflammation and hepatocyte damage to the fat. MASH can progress to fibrosis. Fibrosis can advance to cirrhosis. Cirrhosis is irreversible.

Effective weight loss is still the most reliable treatment that exists. Semaglutide earned FDA approval for MASH in 2024, the only drug to do so. The question SYNCHRONIZE-MASLD was built to answer is whether survodutide, with its glucagon receptor mechanism, can hit MASLD-specific endpoints in a Phase 3 trial of people with active liver disease.

What survodutide does differently in the liver

Semaglutide, tirzepatide, and the rest of the GLP-1 class work through one core route: cutting appetite and slowing gastric emptying. Liver fat comes down as a consequence of less food in, less fat to store. The liver benefits are real, but they are indirect.

Survodutide adds glucagon receptor agonism. Glucagon receptors are concentrated in the liver. Activating them tells hepatocytes to burn fatty acids directly, raising energy expenditure in the liver itself. That mechanism attacks hepatic fat from the inside, independently of how much food the patient eats. It is why survodutide already showed 63% liver fat reduction in the MRI substudy of SYNCHRONIZE-1, the obesity trial, even though that trial enrolled patients based on BMI, not liver disease.

SYNCHRONIZE-MASLD asked whether that liver-targeting mechanism holds up when the population is specifically people selected for fatty liver disease and metabolic risk.

What SYNCHRONIZE-MASLD found

The trial enrolled 216 adults with obesity and MASLD, defined by evidence of liver inflammation or fibrosis on imaging. Patients were randomized 2:1 to once-weekly survodutide 6mg or placebo for 48 weeks. The co-primary endpoints were a 30% or greater reduction in MRI-measured liver fat and percentage change in body weight. Both were met.

84.2% of treated patients cleared the 30% liver fat threshold. On placebo, 24.3% did. That gap is large by any clinical measure, but the absolute survodutide number is the more striking figure. Most lifestyle interventions in MASLD populations struggle to produce 30% liver fat reductions in more than a third of patients. Here it happened in more than four in five.

61% normalized their liver fat entirely, dropping below 5%, the threshold where MASLD is no longer diagnosable. 5.7% of the placebo group reached that threshold. Body weight fell 12.2% on survodutide and 1% on placebo.

The fibrosis data: what happened to scarring

Liver fat is the proximate measure. Fibrosis is the outcome that carries mortality risk. SYNCHRONIZE-MASLD enrolled patients with F2 and F3 fibrosis, moderately advanced scarring. In that subgroup, 64.5% of survodutide-treated patients showed no worsening of MASH at week 48.

Stabilization over 48 weeks matters in a disease that tends to progress, but it is not the same as fibrosis reversal. SYNCHRONIZE-MASLD was designed around imaging endpoints: liver fat percentage and body weight change. Fibrosis was a secondary outcome. The trial was not powered to show fibrosis improvement the way ESSENCE, semaglutide's Phase 3, was. That is a real limitation of the dataset.

Boehringer Ingelheim has the LIVERAGE trial running in patients with MASH and cirrhosis, which is the harder version of that question. LIVERAGE results are years away. The SYNCHRONIZE-MASLD fibrosis data tells us the drug is not making things worse in F2/F3 patients and is producing imaging endpoints consistent with what precedes histologic improvement. That is meaningful but incomplete.

How survodutide compares to semaglutide for MASH

Semaglutide is the only FDA-approved drug for MASH. The ESSENCE trial enrolled 800 adults and used biopsy-confirmed histologic endpoints. 33% of semaglutide patients achieved MASH resolution without fibrosis worsening, vs 16% on placebo. 37% showed fibrosis improvement by at least one stage, vs 22% on placebo.

Those are different endpoints in a different population. ESSENCE and SYNCHRONIZE-MASLD cannot be directly compared. What can be said is that survodutide's imaging numbers are striking, and that the glucagon mechanism adds a hepatic fat-burning component that semaglutide does not have. Whether that translates to better biopsy outcomes than semaglutide in a head-to-head trial is unknown. No such trial exists.

For the full story on the semaglutide MASH approval, including the ESSENCE data and what it took to get the indication, that is covered separately.

What the approval path looks like from here

Boehringer Ingelheim has not yet filed for FDA approval of survodutide for any indication. The cardiovascular outcomes trial, SYNCHRONIZE-CVOT, is still running. Standard practice is to have cardiovascular safety data in hand before filing for an obesity or metabolic drug, and Boehringer has indicated it plans to file for the obesity indication before a dedicated MASLD indication.

For anyone managing MASLD or MASH today, survodutide is not accessible outside of a clinical trial. Semaglutide is the approved option with the most evidence for a liver indication. Tirzepatide has shown liver fat improvements in substudy data from SURMOUNT-1 but does not carry a dedicated MASLD or MASH approval.

Why glucagon keeps producing large liver numbers

Across survodutide's trial program, the liver data is consistent in a way that is hard to attribute to chance. SYNCHRONIZE-1 showed 63% liver fat reduction in the MRI substudy of the obesity trial. SYNCHRONIZE-MASLD enrolled patients specifically for liver disease and showed 84.2% hitting the liver fat threshold and 61% normalizing entirely. The mechanism explains the consistency: glucagon receptor activation in hepatocytes drives fatty acid oxidation directly, not as a downstream consequence of eating less.

Retatrutide, Eli Lilly's triple agonist in late-stage development, also includes glucagon receptor agonism. The Phase 2 liver fat substudy for retatrutide showed 86% liver fat reduction and 93% normalization. Two drugs sharing the same hepatic mechanism are producing similar liver signals. That is not coincidental.

For patients specifically dealing with fatty liver disease rather than obesity alone, the glucagon receptor angle in survodutide and retatrutide is the most mechanistically compelling development in the GLP-1 landscape right now. Whether that advantage survives a head-to-head with semaglutide on biopsy endpoints is the question the field will spend the next few years answering. Read the full SYNCHRONIZE-1 obesity results for the broader weight, visceral fat, and muscle data from the parallel Phase 3 trial.